<P>Killed whole-cell oral cholera vaccine (OCV) has been a key component of a comprehensive package including water and sanitation measures for recent cholera epidemics. The vaccine, given in a two-dose regimen, has been evaluated in a large num...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107478020
Desai, Sachin N. ; Akalu, Zenebe ; Teshome, Samuel ; Teferi, Mekonnen ; Yamuah, Lawrence ; Kim, Deok Ryun ; Yang, Jae Seung ; Hussein, Jemal ; Park, Ju Yeong ; Jang, Mi Seon ; Mesganaw, Chalachew ; Taye, Hawult ; Beyene, Demissew ; Bedru, Ahmed ; Singh, Ajit Pal ; Wierzba, Thomas F. ; Aseffa, Abraham
2015
-
SCI,SCIE,SCOPUS
학술저널
527-533(7쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P>Killed whole-cell oral cholera vaccine (OCV) has been a key component of a comprehensive package including water and sanitation measures for recent cholera epidemics. The vaccine, given in a two-dose regimen, has been evaluated in a large num...
<P>Killed whole-cell oral cholera vaccine (OCV) has been a key component of a comprehensive package including water and sanitation measures for recent cholera epidemics. The vaccine, given in a two-dose regimen, has been evaluated in a large number of human volunteers in India, Vietnam, and Bangladesh, where it has demonstrated safety, immunogenicity, and clinical efficacy. We conducted a double-blind randomized placebo-controlled trial in Ethiopia, where we evaluated the safety and immunogenicity of the vaccine in 216 healthy adults and children. OCV was found to be safe and elicited a robust immunological response against <I>Vibrio cholerae</I> O1, with 81% adults and 77% children demonstrating seroconversion 14 days after the second dose of vaccine. This is the first study to evaluate safety and immunogenicity of the vaccine in a population outside Asia using a placebo-controlled, double-blind, randomized study design.</P>